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Summary
Objective: To investigate whether there is a possible viral transmission using mesenchymal stem cells (MSCs) in autologous or allogeneic
transplantation in the context of osteoarthritis (OA) patients. The presence of parvovirus B19 (B19), varicella zoster virus (VZV), and human
herpesvirus-6 (HHV-6) was studied in MSCs from bone marrow of patients with OA and healthy controls.
Methods: MSCs were prepared from bone marrow aspirates obtained from 18 patients undergoing joint replacement as a result of OA and
from 10 healthy controls. DNA was extracted from primary MSCs’ culture established from these cells and quantitative real-time polymerase
chain reaction was performed to analyse the prevalence and viral load of B19, VZV and HHV-6.
Results: The prevalence of total viral DNA among patients with OA was 16.7% (3/18), with a mean viral load of 29.7 copies/mg of DNA. One
out of 18 was positive for B19 (viral load, 61.2 copies/mg of DNA), two for VZV (mean viral load, 14.4 copies/mg of DNA), and none for HHV-6.
The prevalence of total viral DNA in the control group was 20% (2/10), with a mean viral load of 13.4 copies/mg of DNA. Both positive results
were of B19 parvoviruses. There were no statistically signiﬁcant differences among patients and controls.
Conclusions: This ﬁrst approach to the viral prevalence in MSCs of bone marrow in OA patients and healthy controls seems to show a very low
risk of viral transmission or reactivation in a possible MSCs’ transplantation.
ª 2006 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is associated with bone and articular
cartilage degenerative changes which develop due to the
complex interaction of genetic, metabolic, biochemical, bio-
mechanical and inﬂammatory factors1,2. The disease has
important social and economic consequences over the in-
creasingly aged occidental populations3.
Current investigations on mesenchymal stem cells
(MSCs) offer a new perspective for bone and cartilage tis-
sue regeneration. MSCs have the capacity to differentiate
into a variety of connective tissue cells including bone, car-
tilage, tendon, muscle, and adipose tissue4. These cells are
easily isolated from bone marrow and can be expanded in
culture through many generations, while retaining their ca-
pacity to differentiate when exposed to appropriate signals.
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2006.4Several reports have shown that local delivering of autolo-
gous stem cells expanded previously in culture might be
useful for repairing focal defects in articular cartilage of pa-
tients with knee OA5, as well as in animal models of OA in-
duced by injury to the meniscus6. Furthermore, there is
growing evidence of the hypoimmunogenic nature of
MSCs, a fact that bears key implications in terms of alloge-
neic therapy. Some reports have described the clinical use
of allogeneic donor-mismatched cells with little evidence of
host immune rejection. For example, allogeneic bone mar-
row transplantation in children with brittle-bone disease
(osteogenesis imperfecta) resulted in engraftment of do-
nor-derived MSCs and increasing new bone formation7.
Major disadvantage of allogeneic approaches relates to
potential risks of disease transmission from donors to
recipients.
It has been described that patients undergoing autologous
stem cells’ transplants might experience viral infections be-
cause of reactivation of the viruses8,9, and that allogeneic
stemcell transplantation is often complicatedbyherpesvirus re-
activation10. In this report, we have analyzed the presence and
viral loadof threeviruses thatmight potentiallybe transmittedby
MSCs from bone marrow: parvovirus B19 (B19), varicella75
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tients with OA and healthy controls using a quantitative real-
time polymerase chain reaction (PCR).
Patients and methods
PATIENTS
A total of 18 patients with OA (mean age 74.7 years, range
61e89) and 10 healthy controls with not known history of
joint disease (mean age 66.6, range 44e90) were recruited
from the Service of Orthopaedic Surgery of Hospital Clı´nico
San Carlos. The diagnosis was based on clinical and radio-
logical criteria. Most patients with OA were treated with anal-
gesic and/or nonsteroidal anti-inﬂammatory drugs. None of
the patients had received corticosteroids or cytostatic drugs
during previous months. Patients with systemic inﬂamma-
tory diseases such as rheumatoid arthritis or spondyloarthro-
pathies were excluded. The study protocol was reviewed
and approved by our institutional board, and informed con-
sent was obtained from all the subjects enrolled in the study.
SPECIMENS
Fresh bone marrow aspirates (5e10 ml) were obtained
from the distal femur of the patients with OA during total
knee replacement surgery and from healthy controls during
tissue harvest in the process of multiorganic donation
(n¼ 3) or from proximal femur in the surgery for the subca-
pital fracture of the hip (n¼ 7).
CELL CULTURE
Human MSCs were established from bone marrow aspi-
rates of OA patients and donors according to the method
of Pittenger et al.11. Brieﬂy, the aspirates were washed
once with Dulbecco’s modiﬁed Eagle’s medium-low glucose
(DMEM-LG; Gibco BRL, Paisley, UK) containing 10% fetal
bovine serum (FBS) (SigmaeAldrich, St. Louis, MO), and
antibiotic supplements (control medium). The cell-containing
fraction was layered onto a 70% percoll solution (Sigmae
Aldrich) and centrifuged at 500 g for 15 min at 23C. The
low-density fraction was collected, washed once with control
medium, and plated into culture dish (100 mm). Cultures
were maintained at 37C in a humidiﬁed atmosphere and
5% CO2. At the end of primary culture, adherent colonies
were detached by treatment with 0.25% trypsin containing1 mM EDTA for 5 min at 37C, and subsequently replated
for continued passaging 1:2. Medium changes were
performed twice weekly. Conﬂuent cells (approximately
1 106) at the third passage were used for the experiments.
DNA EXTRACTION
DNA was extracted, using Qiagen columns (QIAamp
DNA Mini Kit, Qiagen GmbH, Germany), from primary
MSCs’ culture, established from bone marrow from patients
with OA and controls, according to the protocols supplied by
the manufacturer.
QUANTITATIVE REAL-TIME PCR
DNAs were analyzed by quantitative real-time PCR for
the presence of B19, VZV and HHV-6 genomes, and human
b-actin gene as internal control, with the primers, TaqMan
probes (Table I), and cycling conditions that we described
elsewhere12. The mean concentration of the target DNA in
each one of the PCRs was 280 ng; all the samples were an-
alyzed in duplicate for each one of the viruses. The quanti-
tative assessment was performed in a Rotor-Gene 3000
real-time cycler (Corbett Research, Sydney, Australia).
The sensitivities of the assay were one copy for the detec-
tion of HHV-6, two copies for B19, and ﬁve copies for VZV.
STATISTICAL ANALYSIS
Categorical variables were presented as frequency distri-
bution and quantitative variables as means standard devi-
ation (SD) if they ﬁt a normal distribution, and median
[25e75 interquartile deviation, IQD] if distribution was
non-normal; odds ratios (OR) are presented with its 95%
conﬁdence interval (CI). Differences between groups were
analyzed using the two-tailed Student’s t test and the Man-
neWhitney U test for normal and non-normal quantitative
variables, respectively. The Chi-square test was used to
compare categorical variables. A two-sided P value of
0.05 was the criterion for statistical signiﬁcance in all cases.
Results
CULTURE AND PASSAGING OF HUMAN MSCs
Marrow aspirates were obtained from 18 patients under-
going joint replacement due to OA and 10 controls withoutTable I
Primers and probes sequences
Primer/probe Sequence (50/ 30) Size (bp)
B19 F-primer TGGCCCATTTTCAAGGAAGT 74
R-primer CTGAAGTCATGCTTGGGTATTTTTC
Probe FAM-CCGGAAGTTCCCGCTTACAAC-TAMRA
VZV F-primer GGTGGAGACGACTTCAATAGC 99
R-primer CTCGATTTTCCAAGAGAGAC
Probe FAMeCGTAATTCGATCGACCGGGATATCATACTC-TAMRA
HHV-6 F-primer CGAAACGCCTACACAGAAT 115
R-primer CAAAGCCAAATTATCCAGAGCG
Probe FAM e ATTCCTTCGGGTGTGACG e MGB-DQ
b-Actin F-primer TCACCCACACTGTGCCCATCT 106
R-primer GTGAGGATCTTCATGAGGTAGTCAGTC
Probe FAM-ATGCCCTCCCCCATGCCATCCTGCGT-TAMRA
F-primer¼ forward PCR primer; R-primer¼ reverse PCR primer; bp¼ base pairs.
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during medium changes and the subsequent passaging.
The cells isolated from these marrow aspirates formed con-
ﬂuent cultures of adherent cells with a ﬁbroblastic morphol-
ogy in approximately 2 weeks. MSCs were successfully
expanded from all these subjects.
STUDY OF B19, VZV, AND HHV-6
The results are shown in Table II. The prevalence of total
viral DNA among patients with OA was 16.7% (3/18), with
a mean viral load of 29.7 copies/mg of DNA. One out of 18
was positive for B19 (viral load, 61.2 copies/mg of DNA),
two for VZV (mean viral load, 14.4 copies/mg of DNA), and
none for HHV-6. The prevalence of total viral DNA in the
control group was 20% (2/10), with a mean viral load of
13.4 copies/mg of DNA. Both positive results were of B19
parvoviruses. There were no statistically signiﬁcant differ-
ences among patients and controls.
Discussion
Transplanted MSCs carried viruses, which may cause
infection in the host, and viral infection of MSCs might
also affect the ﬁnal success of transplantation. Previous
reports indicate that patients undergoing autologous stem
cells’ transplantation can experience viral infections be-
cause of virus reactivation8,9. In addition, allogeneic stem
cell transplantation is often complicated by reactivation of
herpesviruses10. HHV-6 infection after bone marrow trans-
plantation has been associated in some studies with fever
and rash resembling acute graft-vs-host disease, as well
as interstitial pneumonitis, encephalitis, cytomegalovirus
(CMV) disease, and bone marrow suppression13. Several
large case analyses could not demonstrate any statistical
relationship between HHV-6 infection and such clinical
events14. However, a correlation between the amount of vi-
rus in peripheral blood mononuclear cells before bone mar-
row transplantation and subsequent viral infection has been
previously described15. VZV frequently causes severe in-
fection in patients who have undergone bone marrow
transplantation. Ofﬁdani et al.16 studied the frequency,
characteristics, and risk factors associated with VZV infec-
tion in 164 patients undergoing autologous peripheral blood
progenitor cell transplantation. Roughly, 15% developed
VZV infection and the actuarial risk was 10% at 1 year.
None of the patients had visceral dissemination or died be-
cause of VZV infection, although one-third of the patients
developed postherpetic neuralgia. Arnold et al.17 demon-
strated that autologous peripheral blood progenitor cells
are a potential source of parvovirus infection, which may
cause signiﬁcant disease after autologous bone marrow
Table II
Prevalence and viral load of B19, VZV, and HHV-6 in MSCs of OA
patients and controls
OA patients Controls %OA vs %Controls
Pos*/n (%) VLy Pos/n (%) VL P OR (CI 95%)
Total 3/18 (16.7) 29.7 2/10 (20) 13.4 0.825 0.8 (0.1e8.8)
B19 1/18 (5.6) 61.2 2/10 (20) 13.4 0.236 0.2 (0.1e4.2)
VZV 2/18 (11.2) 14.4 0/10 (0) e 0.274 e
HHV-6 0/18 (0) e 0/10 (0) e e e
*Pos¼ positive samples.
yVL¼mean viral load, in copies/mg of DNA.transplantation. B19 is a rare but clinically signiﬁcant infec-
tion that manifests as refractory anemia during the post-
transplantation period. The use of PCR for diagnosis is
particularly helpful in immunosuppressed transplant pa-
tients who may fail to mount antibodies against B19 during
active infection18.
Herein, we report the study of B19 and other two viruses
from Herpesviridae family (VZV and HHV-6) in MSCs from
bone marrow of OA patients and controls without joint dis-
ease. As shown in the Results section, we only found the
presence of viral genomes in 3/18 OA patients (16.7%), al-
most the same prevalence (20%) of viral DNA found in the
control group of subjects without joint disease. One sample
of MSCs of OA patients and two of controls were positive for
B19 DNA. Viral DNA for VZV was detected in two samples
of OA patients. On the other hand, HHV-6 DNA was not de-
tected in MSCs of patients and controls, and the viral loads
were very low in both groups. Recently, Sundin et al.19 have
analyzed MSCs from healthy seropositive donors with PCR
for CMV, herpes simplex virus type 1 (HSV-1), herpes sim-
plex virus type 2, Epstein-Barr virus (EBV) and VZV. Their
results indicate that viral DNA cannot be detected in healthy
seropositive individual and that the risk of herpesvirus trans-
mission by transplantation of MSCs from healthy seroposi-
tive donors is low. In other study, Behzad-Behbahani et al.8
examined viral DNA from bone marrow progenitor cells, pe-
ripheral blood leukocytes, and plasma sample from 30 allo-
geneic bone marrow donors, using nested PCR, to detect
B19, HHV-6, VZV, human cytomegalovirus (HCMV), and
EBV. They cannot detect HHV-6 DNA in any collected
specimen by simple PCR. However, B19 and VZV DNA
were, respectively, detected in the plasma of four (13.3%)
and one (3.3%) of the 30 bone marrow donors but not in
bone marrow progenitor cells.
In conclusion, these results provide evidence supporting
the very low risk of viral transmission or reactivation in
transplantation of autologous or allogeneic MSCs in pa-
tients with various disorders requiring tissue regeneration.
However, additional studies are needed to conﬁrm these re-
sults, since this is the ﬁrst approach to the viral prevalence
in MSCs of bone marrow from OA patients.
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